Clinical Data PresentationAPLT will present the full 12-month clinical data from the Phase 3 INSPIRE study and additional new topline data at 18 and 24 months for patients.
Leadership StrengtheningThe company announced the appointments of Todd F. Baumgartner, M.D., M.P.H. as chief regulatory officer and Reena Thomas Colacot as vice president and head of quality, enhancing leadership in key areas.
Operational StrategyNew management has been focused on executing on their operational, regulatory, and clinical goals, positioning APLT in a stronger position across these strategies.